<DOC>
	<DOCNO>NCT00005085</DOCNO>
	<brief_summary>Phase II trial study effectiveness rebeccamycin analog treat patient metastatic locally recurrent colorectal cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Rebeccamycin Analog Treating Patients With Metastatic Locally Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient metastatic locally recurrent colorectal cancer treat rebeccamycin analogue . II . Determine toxicity regimen patient population . III . Determine effect regimen progression-free overall survival patient . OUTLINE : This multicenter study . Patients receive rebeccamycin analogue IV day 1 . Treatment repeat every 21 day maximum 12 course absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic locally recurrent adenocarcinoma colon rectum No curable stage disease At least 1 unidimensionally measurable lesion At 20 mm conventional technique OR least 10 mm spiral CT scan No tumor lesion previously irradiate area except clearly measurable lesion document histologically consistent recurrent tumor previously irradiate bed within pelvis The follow consider nonmeasurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 12 week WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Bilirubin normal AST/ALT great 2.5 time upper limit normal Creatinine normal OR creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study Eligible placement central venous catheter No prior allergic reaction attribute compound similar chemical biologic composition rebeccamycin analogue No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : No concurrent prophylactic growth factor ( e.g. , epoetin alfa ) except clinically define indication ( e.g. , filgrastim ( GCSF ) febrile neutropenia ) At least 4 week since prior chemotherapy ( e.g. , fluorouracil , oral fluoropyrimidines , irinotecan , oxaliplatin ) ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy No concurrent hormones except clinically define indication At least 4 week since prior radiotherapy ( include bony site , whole pelvis , lung , liver , spinal cord/brain ) recover No prior total dose radiotherapy 7,000 cGy No prior radiotherapy 40 % total bone marrow No prior radiotherapy site measurable disease No concurrent radiotherapy Recovered prior therapy 1 prior adjuvant treatment allow 1 prior treatment advance disease allow At least 4 week since prior investigational agent No concurrent investigational antineoplastic drug No concurrent investigational agent No concurrent commercial agent colorectal cancer No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>